These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 24396495)

  • 81. Role of FDG PET-CT in asymptomatic epithelial ovarian cancer with rising serum CA-125: a pilot study.
    Ghosh J; Thulkar S; Kumar R; Malhotra A; Kumar A; Kumar L
    Natl Med J India; 2013; 26(6):327-31. PubMed ID: 25073988
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Revisiting the clinical value of 18F-FDG PET/CT in detection of recurrent epithelial ovarian carcinomas: correlation with histology, serum CA-125 assay, and conventional radiological modalities.
    Antunovic L; Cimitan M; Borsatti E; Baresic T; Sorio R; Giorda G; Steffan A; Balestreri L; Tatta R; Pepe G; Rubello D; Cecchin D; Canzonieri V
    Clin Nucl Med; 2012 Aug; 37(8):e184-8. PubMed ID: 22785525
    [TBL] [Abstract][Full Text] [Related]  

  • 83. The application value of the detection of the level of tissue polypeptide antigen, ovarian cancer antigen X1, cathepsin L and CA125 on the diagnosis of epithelial ovarian cancer.
    Lv XL; Zhu Y; Liu JW; Ai H
    Eur Rev Med Pharmacol Sci; 2016 Dec; 20(24):5113-5116. PubMed ID: 28051260
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Treatment options in recurrent ovarian cancer: latest evidence and clinical potential.
    Luvero D; Milani A; Ledermann JA
    Ther Adv Med Oncol; 2014 Sep; 6(5):229-39. PubMed ID: 25342990
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Management of recurrent epithelial ovarian cancer.
    Vargas-Hernández VM; Moreno-Eutimio MA; Acosta-Altamirano G; Vargas-Aguilar VM
    Gland Surg; 2014 Aug; 3(3):198-202. PubMed ID: 25207212
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Diagnostic and prognostic evaluation of fluorodeoxyglucose positron emission tomography/computed tomography and its correlation with serum cancer antigen-125 (CA125) in a large cohort of ovarian cancer patients.
    Evangelista L; Palma MD; Gregianin M; Nardin M; Roma A; Nicoletto MO; Nardelli GB; Zagonel V
    J Turk Ger Gynecol Assoc; 2015; 16(3):137-44. PubMed ID: 26401105
    [TBL] [Abstract][Full Text] [Related]  

  • 87. New perspectives on targeted therapy in ovarian cancer.
    Coward JI; Middleton K; Murphy F
    Int J Womens Health; 2015; 7():189-203. PubMed ID: 25678824
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Ovarian cancer: new developments in clear cell carcinoma and hopes for targeted therapy.
    Yamashita Y
    Jpn J Clin Oncol; 2015 May; 45(5):405-7. PubMed ID: 25583423
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Epithelial ovarian cancer: An overview.
    Desai A; Xu J; Aysola K; Qin Y; Okoli C; Hariprasad R; Chinemerem U; Gates C; Reddy A; Danner O; Franklin G; Ngozi A; Cantuaria G; Singh K; Grizzle W; Landen C; Partridge EE; Rice VM; Reddy ES; Rao VN
    World J Transl Med; 2014 Apr; 3(1):1-8. PubMed ID: 25525571
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
    Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
    Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Bevacizumab in combination with chemotherapy for the treatment of advanced ovarian cancer: a systematic review.
    Aravantinos G; Pectasides D
    J Ovarian Res; 2014; 7():57. PubMed ID: 24864163
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Advanced epithelial ovarian cancer: from standard chemotherapy to promising molecular pathway targets--where are we now?
    Syrios J; Banerjee S; Kaye SB
    Anticancer Res; 2014 May; 34(5):2069-77. PubMed ID: 24778008
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Ovarian cancer.
    Jayson GC; Kohn EC; Kitchener HC; Ledermann JA
    Lancet; 2014 Oct; 384(9951):1376-88. PubMed ID: 24767708
    [TBL] [Abstract][Full Text] [Related]  

  • 94. "Platinum resistant" ovarian cancer: what is it, who to treat and how to measure benefit?
    Davis A; Tinker AV; Friedlander M
    Gynecol Oncol; 2014 Jun; 133(3):624-31. PubMed ID: 24607285
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Blocking Oncostatin M receptor abrogates STAT3 mediated integrin signaling and overcomes chemoresistance in ovarian cancer.
    Geethadevi A; Ku Z; Tsaih SW; Parashar D; Kadamberi IP; Xiong W; Deng H; George J; Kumar S; Mittal S; Zhang N; Pradeep S; An Z; Chaluvally-Raghavan P
    NPJ Precis Oncol; 2024 Jun; 8(1):127. PubMed ID: 38839865
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Clinical practice guidelines for molecular tumor marker, 2nd edition review part 2.
    Kikuchi Y; Shimada H; Yamasaki F; Yamashita T; Araki K; Horimoto K; Yajima S; Yashiro M; Yokoi K; Cho H; Ehira T; Nakahara K; Yasuda H; Isobe K; Hayashida T; Hatakeyama S; Akakura K; Aoki D; Nomura H; Tada Y; Yoshimatsu Y; Miyachi H; Takebayashi C; Hanamura I; Takahashi H
    Int J Clin Oncol; 2024 May; 29(5):512-534. PubMed ID: 38493447
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Discordance between GCIG CA-125 progression and RECIST progression in the CALYPSO trial of patients with platinum-sensitive recurrent ovarian cancer.
    Zebic DS; Tjokrowidjaja A; Francis KE; Friedlander M; Gebski V; Lortholary A; Joly F; Hasenburg A; Mirza M; Denison U; Cecere SC; Ferrero A; Pujade-Lauraine E; Lee CK
    Br J Cancer; 2024 Feb; 130(3):425-433. PubMed ID: 38097739
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Polymeric nanoparticle-based electrochemical sensor for the detection of CA 125.
    Türkcan C; Akgöl S
    Turk J Chem; 2023; 47(1):137-147. PubMed ID: 37720868
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Prognostic significance of carbohydrate antigen 125 in stage D heart failure.
    Zhang J; Li W; Xiao J; Hui J; Li Y
    BMC Cardiovasc Disord; 2023 Feb; 23(1):108. PubMed ID: 36841766
    [TBL] [Abstract][Full Text] [Related]  

  • 100. 'It made me feel part of the team, having my homework to do' - women and specialist nurse experiences of remote follow-up after ovarian cancer treatment: a qualitative interview study.
    Kennedy F; Shearsmith L; Holmes M; Velikova G
    Support Care Cancer; 2022 Dec; 31(1):2. PubMed ID: 36512093
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.